King Luther Capital Management Corp Acquires 8,887 Shares of DexCom, Inc. (NASDAQ:DXCM)

King Luther Capital Management Corp lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.2% in the 4th quarter, HoldingsChannel reports. The fund owned 222,132 shares of the medical device company’s stock after purchasing an additional 8,887 shares during the period. King Luther Capital Management Corp’s holdings in DexCom were worth $17,275,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares during the last quarter. Jennison Associates LLC boosted its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares during the last quarter. Groupama Asset Managment grew its holdings in DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after buying an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP raised its position in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock valued at $219,716,000 after acquiring an additional 91,051 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DXCM shares. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,083 shares of company stock valued at $3,826,604 over the last three months. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.26 on Wednesday. The firm has a market capitalization of $27.46 billion, a PE ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $84.53 and a two-hundred day moving average price of $76.98. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.